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Abstract 
Background: During intra-erythrocytic replication Plasmodium falciparum escapes the human host immune system 
by switching expression of variant surface antigens (VSA). Piecemeal acquisition of variant specific antibody responses 
to these antigens as a result of exposure to multiple re-infections has been proposed to play a role in acquisition of 
naturally acquired immunity.
Methods: Immunofluorescence was used to explore the dynamics of anti-VSA IgG responses generated by children 
to (i) primary malaria episodes and (ii) recurrent P. falciparum infections.
Results: Consistent with previous studies on anti-VSA responses, sera from each child taken at the time of recov-
ery from their respective primary infection tended to recognize their own secondary parasites poorly. Additionally, 
compared to patients with reinfections by parasites of new merozoite surface protein 2 (MSP2) genotypes, baseline 
sera sampled from patients with persistent infections (recrudescence) tended to have higher recognition of heterolo-
gous parasites. This is consistent with the prediction that anti-VSA IgG responses may play a role in promoting chronic 
asymptomatic infections.
Conclusions: This pilot study validates the utility of recurrent natural malaria infections as a functional readout for 
examining the incremental acquisition of immunity to malaria.
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Background
Children who grow up in malaria endemic areas develop 
naturally acquired immunity to severe forms of the dis-
ease. This immunity takes several years to build up, 
even in hyperendemic areas, and probably never con-
fers sterile immunity. Thus, many individuals in malari-
ous areas carry asymptomatic infections. The transition 
from malaria to asymptomatic infection is still poorly 
understood. The staggered age distribution of severe 
malaria, mild malaria and asymptomatic infection sug-
gests distinctive immunological mechanisms that (i) con-
fer protection against pathogenic features of infection (ii) 
limit parasite replication leading to control of parasite 
burden. The role of antibodies is demonstrated through 
studies in which purified IgG from immune adults was 
used to bring about rapid reduction in parasitaemia and 
symptoms of malaria [1, 2]. One novel way to explore 
this transition further is through observation of recru-
descences, which can occur when drug treatment fails to 
eliminate a blood stage infection [3].
A major target for protective antibodies against malaria 
are the variant surface antigens (VSA) that are anchored 
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in the cell membrane of infected erythrocytes. These 
antigens mediate adhesive parasite-host interactions 
thought to be essential for evading innate immune clear-
ance mechanisms in the spleen. Variant specific anti-VSA 
immune responses are thought to play an important role 
in the development of naturally acquired immunity to 
malaria [4–6]. Following an episode of malaria individu-
als develop anti-VSA antibodies that are highly specific 
to the isolate that caused that episode of malaria (hence-
forth termed homologous parasites) [4–8]. Carriage of 
anti-VSA antibodies imposes a selection pressure on the 
infecting blood stage parasite population restricting the 
diversity of VSAs expressed [4, 5, 9]. More directly an 
in vivo switch in VSA expression has been observed with 
accompanying acquisition of antibodies specific to the 
respective VSAs [10].
Plasmodium falciparum Erythrocyte Membrane Pro-
tein 1 (PfEMP1), encoded by the large multigene var 
family is thought to be the major VSA [11]. Each hap-
loid genome contains about 60 var genes, and expres-
sion is mutually exclusive at the individual parasite level 
(reviewed in [12]). Immune selection of PfEMP1 expres-
sion by host antibodies has been shown indirectly by 
correlation of expression of specific subsets of var genes 
with age [13, 14], and by negative association with anti-
VSA antibody repertoire [14–16].
Here, to explore the transition from malaria disease 
to asymptomatic infection and the relationship between 
recrudescence and immunity to VSA, anti-VSA antibody 
acquisition was studied in children within the age bracket 
where the transition from symptomatic to asymptomatic 
infections occurs, who presented to hospital with mild 
malaria, and who returned within 84  days with recur-
rent parasitaemia. The kinetics of antibody acquisition 
to the baseline and recurrent isolates was studied. The 
anti-VSA antibody repertoire of sera from patients that 
carried parasites that recrudesced was compared to the 
repertoire of those that experienced reinfection by new 
genotypes only.
Methods
Origin and storage of samples
In this study, samples from children presenting with mild 
malaria who were included in a Phase III, randomized, 
non-inferiority trial was used to assess the efficacy and 
safety of dihydroartemisinin-piperaquine (Artekin) in 
comparison with artemether–lumefantrine (Coartem©) 
in Pingilikani, Kenya, with a follow up period of 84 days. 
This study has been described in detail elsewhere [17]. 
Children were enrolled if presenting with uncomplicated 
malaria and fulfilling all criteria as described [17]. They 
were monitored for 3 days on-site during the administra-
tion of therapy and the mother/guardian was asked to 
return with the child for scheduled visits on days 7, 14, 
21, 28, 35, 42 and 84 post-enrollment, or if any symptoms 
occurred. During this follow up period, samples (serum, 
blood samples for gDNA extraction and live P. falci-
parum isolates) were collected at any time the children 
were parasitaemic according to microscopic examination 
as described [17]. Serum was additionally collected on 
days 3, 7, 14, 28 and 42. All samples were anonymized. 
Serum was stored at − 80 °C. Full blood containing par-
asitized red blood cells was collected and mixed with 
cryosolution (28% glycerol, 3% (w/v) sorbitol, 0.64% 
saline) at a volumetric ratio of about 1:4 (packed cell 
volume:cryosolution) and stored in liquid nitrogen.
Description of isolates used
During the follow up period recurrent parasitaemias 
were screened for recrudescences using MSP2 genotyp-
ing. Initial screening was done using the RFLP method 
described by Felger et al. [18] and isolates from 9 patients 
were selected for the study described here if the patients 
harboured a recrudescence within the first 42 days of fol-
low up and if the parasitaemia was > 0.1% (Tables 1 and 
2). Flow cytometry data was obtained from 7 of these 
patients, and out of these, 6 patients could later be con-
firmed as harbouring recrudescence by a superior resolu-
tion capillary electrophoresis MSP2 genotyping method 
[19] using oligo N5 with JOE instead of VIC, on the ABI 
genetic analyzer 3130 (Additional file 1: Table S1). How-
ever, it cannot be excluded that this will include false 
recrudescences by infections caused by parasites contain-
ing the same MSP2 alleles.
Description of sera used
Sera from these 7 patients, taken at day of recruitment 
and at follow-up visits (days 0, 3, 7, 14, 28, 42 and 84, and 
when patient visited clinic with parasitaemia during the 
follow-up period), were used to study antibody acquisi-
tion towards the respective infecting parasites in each 
of these patients over time. Whenever a serum is tested 
against an isolate from the same patient, they are referred 
to as homologous serum and isolate.
To test heterologous recognition of the isolates, i.e., 
testing serum derived from different patients than the 
Table 1 Sample (parasite isolate) characteristics
Mean ± SD
Age of patient (at inclusion in study) 32.9 months ± 9.9
Time to first recurrence 35 days ± 7.0
Number of MSP2 alleles (baseline infections) 2.29 ± 0.95
Number of MSP2 alleles (recurrent infections) 2.25 ± 2.01
Parasitaemia (baseline infections) 3.3%  ± 2.3
Parasitaemia (recurrent infections) 1.4%  ± 1.9
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parasite isolate tested, a panel of heterologous sera 
(Table  3) from 14 (blood group A) and 4 (blood group 
AB) patients were chosen. The panel of 4 sera (blood 
group AB) was used to test parasites from patient 171, 
the only patient with blood group AB (Table  2). All 
sera originated from the same study described above, 
from children who suffered from recurrent parasitae-
mias within the follow up period. Four of the sera in the 
panel originated from patients whose isolates were fur-
ther characterized in this study (119, 150, 178 and 221), 
but when the serum-isolate pair (derived from the same 
patient) were tested this was recorded as homologous 
testing, not heterologous testing. From all 18 patients of 
the heterologous serum panel, sera from day 0 (acute) 
and 14 (convalescent) were tested.
Improved MSP2 analysis using capillary electropho-
resis [19] was performed as described above on the iso-
lates derived from the patients whose sera were included 
in the heterologous serum panel to differentiate between 
sera derived from patients who experienced recrudes-
cences and reinfections during the follow up period.
Flow cytometry
Live isolates were removed from liquid nitrogen, 
washed with ice cold 3.5% NaCl, then washed with cul-
ture medium (RPMI 1640; Gibco), and transferred into 
culture flasks where the isolates were allowed to stabi-
lize for 18–24  h under standard culture conditions [20] 
until trophozoite stage and were then analysed using flow 
cytometry. The procedure of freezing and thawing of the 
already small blood sample volumes originating from 
young children reduces the volume further mainly due to 
red blood cell lysis. For each test, 0.5 µl of the isolate pel-
let were incubated 30 min in 40 µl of PBS (0.1% BSA) with 
0.1  mg/ml Ethidium Bromide (Sigma) and 1  µl serum. 
Negative controls were no serum and non-immune 
pooled blood group AB serum from non-exposed Euro-
pean adults, and a positive control, hyperimmune blood 
group AB adult serum from the Kilifi area also used in 
previous studies [14, 21] was included. After wash-
ing (with PBS, centrifuging at 900g for 5 min) cells were 
incubated in 30 µl of PBS (0.1% BSA) containing antihu-
man-CD45-PC7 (1:30 v/v) (IM3548; Beckman Coulter), 
antihuman IgG-FITC (1:1 v/v) (FA004; the Binding Site) 
and antihuman IgM-SPRD (1:30 v/v) (735986; Beckman 
Coulter). After washing three times (with PBS, centrifug-
ing at 900g for 5 min) samples were resuspended in PBS 
(0.1% BSA) and analysed using an FC500 Flow Cytometer 
(Beckman Coulter).
FlowJo and Excel were used for the initial flow cytom-
etry analysis, where first nucleus containing cells stained 
by ethidium bromide were included, i.e. leukocytes and 
Table 2 Parasite isolates included in the study
a According to MSP2 analysis (capillary electrophoresis)
Patients Female (f)/
male (m)
Age  
(months)
Blood  
group
Day of parasit-
aemia
Parasitaemia 
(%)
Flow  
cytometry 
analysis
Asymptomatic 
(tympanic 
tempera-
ture < 37.5 °C)
No of infecting 
 clonesa
119 F 41 A 0 6.25 Yes 2
35 0.68 Yes No 2
84 2.19 No No 1
150 M 30 A 0 1.69 No 3
42 6.09 Yes No 2
171 M 13 AB 0 2.57 Yes 3
21 0.07 Yes Yes 1
76 2.06 Yes No 2
178 M 35 A 0 2.71 Yes 6
42 4.11 Yes No 1
221 M 38 A 0 6.76 Yes 7
35 0.27 No Yes 4
78 0.14 No Yes 7
233 M 42 0 0 2.22 Yes 3
35 0.47 Yes Yes 7
245 F 31 0 0 1.01 Yes 4
35 0.11 No Yes 6
63 0.67 Yes Yes 2
84 0.11 Yes Yes 9
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infected red blood cells (irbcs) at the trophozoite stage. 
At this stage ring stage parasites were excluded by low 
ethidium bromide staining. Next CD45-containing leu-
kocytes were excluded and finally the IgG recognition 
measured as mean fluorescence intensity (MFI).
The flow cytometer was set to count 1000 irbcs. Sam-
ples where less than 200 irbcs (due to small sample vol-
umes and low parasitaemia) had been measured were 
excluded from analysis. When the volume of cells was 
smaller than expected (pipetting errors on semi-packed 
cell pellets), the last cells measured would give unusu-
ally many counts with high MFI values. To exclude these 
erroneous measurements, samples where the whole pop-
ulation of measured cells (mostly noninfected red blood 
cells) had more than 2.5% IgG positive cells, defined by a 
cut-off at MFI arbitrary units of 12, were excluded from 
analysis. Manual analysis confirmed that no samples 
with high parasitaemia were excluded by this process. 
All flow cytometry results are presented in this study as 
the MFI for each isolate-serum pair, with the individual 
“no serum” sample MFI subtracted. The “no serum” value 
for each parasite isolate was subtracted rather than the 
value of the negative control pool to allow comparison of 
the data with the negative control group. The MFI values 
for each measurement together with parasite isolate and 
serum information is presented in the Additional file  1: 
Table S1.
If the no serum sample was missing (excluded by rea-
sons explained above) or differing by more than 90% from 
the median of all no serum samples, the whole series, i.e. 
all data from the corresponding isolate, was excluded.
To ensure that the measured fluorescence was not sim-
ply an effect of higher parasitaemia in the sample, i.e. an 
experimental artefact, linear regression analysis was per-
formed for fluorescence vs. parasitaemia but no correla-
tion was found (P = 0.27, not shown).
All flow cytometry results used for analysis is presented 
in Additional file 1: Table S1.
Statistical analysis
Graphpad Prism 6.0e for MAC OS X and  Genstat® 16th 
Edition were used for analysis and graphical presenta-
tion. A mixed-effects linear regression model using a 
REstricted Maximum Likelihood (REML) [22] approach 
was used in each analysis described below. In all analyses 
below, random effects for patient and serum were used 
to allow for correlation in reactivity of sera and isolated 
parasites originating from the same patient.
To test for intrinsic differences in the ability of the para-
sites to be recognized, the data were initially transformed 
Table 3 Heterologous serum panel
Sera from day 0 (acute) and day 14 (convalescent) was used from all patients
a According to MSP2 analysis (capillary electrophoresis)
Patients Male (m)/
female (f)
Age 
(months)
Blood 
group
Para-
sitemia 
baseline
Day of recur-
rence
Recurrent infec-
tion asymptomatic 
(tympanic tempera-
ture < 37.5 °C)
Recrudescent 
 infectionsa
Number of infecting  clonesa
Baseline 
infec-
tions
Recurrent infections 
(recrudescent/new 
infections)a
56 M 44 AB 0.10 49 Yes 1 0/1
77 M 34 A 0.08 35 No Yes 5 3/3
105 M 43 AB 1.29 49 Yes 1 0/1
111 M 36 A 0.11 28 Yes 1 0/1
115 AB 1.5 49 Yes 1 0/3
119 F 41 A 6.25 35 No Yes 2 1/1
127 M 46 A 0.85 45 Yes 5 0/1
144 M 48 A 5.05 40 No 2 0/1
150 M 30 A 1.69 42 No 3 0/2
160 F 10 A 0.56 42 No 1 0/4
162 F 25 A 0.06 49 No Yes 2 1/1
169 M 33 A 5.38 42 Yes 2 0/2
178 M 35 A 2.71 42 No Yes 6 1/0
181 F 42 A 0.05 42 Yes Yes 4 4/0
191 F 44 A 3.99 54 Yes 1 0/2
221 M 38 A 6.75 35 Yes Yes 7 2/2
246 M 40 A 0.27 40 No 1 0/10
247 M 32 AB 0.47 56 No 5 0/4
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by natural logarithm,  loge (MFI  +  0.145) to make the 
smallest observation positive and to normalize the distri-
bution. Fixed effects for response type (originating from a 
patient that responded to its parasite isolate vs. a patient 
that did not) and serum day (day 0 or 14), together with 
their interaction were then tested in the model.
The same analysis was performed to test for a difference 
between recognition of baseline vs. recurrent isolates. In 
this case the fixed effects were isolate type (baseline or 
recurrent) and serum day (day 0 or 14).
The ability of homologous sera taken before recurrence 
to recognize the recurrent parasites was also compared to 
that of their overall recognition by heterologous sera with 
a linear mixed effect regression model. In this analysis, 
only sera taken before the recurrent infection were used. 
The data were transformed by  loge (MFI + 0.062) to make 
the smallest observation positive. Fixed effects tested in 
the model were serum type (homologous recognition of 
recurrent isolates vs. recognition of the same recurrent 
isolates by heterologous sera) and serum day (day 0 or 14).
To compare the anti-VSA antibody repertoire of chil-
dren who eliminated the baseline parasites to that of 
those children who did not, a similar linear mixed effect 
regression model was used. The data were transformed 
by  loge (MFI + 0.145) to make the smallest observation 
positive. Fixed effects for serum type (originating from a 
patient that eliminated its parasite infection vs. a patient 
that did not) and serum day (day 0 or 14) were fitted.
Histograms or residuals, fitted-value plots and normal 
plots were performed to test the suitability of the trans-
formed data in the linear mixed effect regression models.
Results
Characterization of parasite isolates
For this study, samples from children presenting with 
mild malaria who were included in a dihydroartemisinin-
piperaquine vs. artemether–lumefantrine drug trial 
were used [17]. In total 14 parasite isolates from 7 of 
these patients were analysed for antibody recognition 
(Tables 1, 2). All the children involved are within the age 
bracket where Plasmodium infections transit from caus-
ing disease to being asymptomatic. Table  2 also shows 
whether the recurrent infections were asymptomatic 
(tympanic temperature < 37.5) at the time of detection.
Characterization of sera
Sera derived from children in the same study were used 
to test antibody recognition of the isolates described 
above. Homologous sera (sera derived from the same 
patient as the parasite isolate tested) were used to test 
acquisition of antibodies to the infecting isolates of the 
respective patients. Sera from all available time points 
during the study follow up were used.
Heterologous sera (sera derived from other patients 
than the tested isolate) were used to test general recog-
nition of the isolates in the population. For this a panel 
of sera from in total 18 patients in the same study were 
chosen to characterize heterologous recognition of the 
parasite isolates (Table 3). Sera from day 0 (acute) and 14 
(convalescent) were used. All the patients contributing 
serum to this panel had recurrent infections during the 
follow-up period of 84 days, and Table 3 shows the day of 
recurrence and whether the detected recurrent infection 
was asymptomatic at the time of detection. Active weekly 
follow-up as in this study is likely to detect an increased 
number of asymptomatic infections, here  >  50% of the 
recurrent infections were asymptomatic.
Antibody acquisition to infecting isolates varies 
between patients
Antibodies to the infected red blood cell (irbc) surface 
were measured by immunofluorescence and flow cytom-
etry. To explore the kinetics of antibody responses to 
irbc sampled at baseline (day 0) and at the time of recur-
rent parasite infections each parasite isolate was tested 
against homologous sera (sera derived from the same 
patient as the parasite isolate tested) sampled at differ-
ent time points. Figure 1a, b shows the kinetics of anti-
body acquisition. 3/6 patients developed antibodies to 
their baseline parasites (blue lines), with antibody acqui-
sition rising over time (patients 119, 221 and 233). The 
other three made either a very weak, or no response at 
all i.e. patients 171, 178 and 245. This variation in anti-
body responses appeared not to be due to intrinsic dif-
ferences in the ability of the parasites to be recognized by 
antibodies because there was no significant correlation 
between the homologous and heterologous recognition 
of these parasite isolates (P = 0.221, mixed-effects linear 
regression model) (Fig.  1c and Additional file  2: Figure 
S1), and there was no overall difference in antibodies to 
baseline vs. recurrent isolates measured in heterologous 
sera (P =  0.215, mixed-effects linear regression model). 
One explanation could be the duration of the infection 
(or more precisely: the infection with the clone or clones 
that were responsible for the malaria episode) before the 
patients presented to us. If diagnosed quickly and com-
bined with the fast acting ACT used in this trial parasites 
could have been removed before an effective antibody 
response was mounted. This hypothesis could not be 
tested here.
Recurrent Plasmodium falciparum infections tend to be 
poorly recognized by pre-existing homologous antibodies
As shown in Fig. 1a recognition of recurrent parasites by 
homologous sera taken earlier than the recurrence was 
generally poor. Figure  2a illustrates this further, where 
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homologous recognition of the individual recurrent iso-
lates is shown and the day of recurrent parasitaemia is set 
at day 0. To explore this further, this pre-existing homol-
ogous recognition of recurrent isolates was compared 
to recognition by a panel of heterologous day 0 (acute) 
and day 14 (convalescent) sera from other patients in 
the same study (Table  3). Recurrent parasites tended to 
be recognized less well by homologous sera than het-
erologous sera, although with only borderline signifi-
cance (Fig. 2b) P = 0.063, mixed-effects linear regression 
model). Overall these observations are consistent with 
the idea that parasites express antigens corresponding to 
gaps in the repertoire of antibodies carried by the host.
Genotyping
All sera used to test heterologous recognition of the iso-
lates described above were derived from patients who 
had also experienced a recurrent, i.e. secondary infec-
tion during follow-up. Those patients who were unable 
to clear their parasites in spite of treatment, resulting in 
a recrudescent infection are of specific interest. There-
fore, MSP2 genotyping analysis was performed on the 
parasite DNA isolated from these patients to differenti-
ate between recrudescence (persistent blood stage infec-
tion) and re-infection (new infection emerging from the 
liver). A recrudescent infection is defined by the presence 
of at least one genotype during follow-up also detected 
before treatment. Thus, 6/18 patients whose sera were 
part of the heterologous serum panel were confirmed to 
have recrudescent infections within the follow-up period 
(Table 3).
Patients carrying recrudescent infections tend to have a 
broader antibody repertoire than patients who cleared 
their infections
Next, the anti-VSA antibody repertoires of the 6 patients 
with recrudescence was compared to the 12 patients who 
cleared their initial infections (Table 3). For this their abil-
ity to recognize the 14 parasite isolates from the 7 patients 
described above was measured (Table  2 and Additional 
a b
c
Fig. 1 Kinetics of antibody acquisition to baseline and recurrent isolates. a Surface recognition of individual parasite isolates by their corresponding 
homologous sera. Sera taken at different time-points after uptake of the child in the study were tested for recognition of the baseline and recurrent 
isolates, measured as mean fluorescence intensity (MFI). The recognition of baseline isolates is depicted in blue and that of recurrences in black. 
Arrows point to the time when the investigated recurrent parasitaemia was detected. b Homologous recognition of all baseline isolates is sum-
marized to better illustrate the separation of responders versus non-responders. c Heterologous recognition of the individual isolates showing that 
isolates are variably recognized by heterologous sera, the median is shown as a horizontal bar. Hyperimmune serum recognition of the individual 
isolates is also shown (red asterisk)
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file 2: Figure S1). The anti-VSA antibody repertoire of the 
sera from children who carried recrudescent infections 
was higher than that of children with only reinfections 
(Fig.  3), although only borderline significant P  =  0.059 
as tested using a linear mixed effect regression model. To 
exclude that this is not simply an effect of reduced drug 
sensitivity of the parasite, existing data from all children 
in the initial study experiencing recurrences [17] was used 
to re-analyse risk of recrudescence as a function of the 
 IC50 values for the long-acting drugs lumefantrine and 
piperaquine. A recrudescence is not determined by the 
sensitivity of the baseline isolate to the long-acting drugs 
used in the study (Additional file 3: Table S2). There was 
no indication of tolerance or resistance in the response to 
dihydroartemisinin in the study [17].
It is possible that submicroscopic infections (unde-
tected microscopically but persisting until the recrudes-
cence was detected), may themselves boost antibodies. 
However, the anti-VSA antibody repertoire in children 
who later had recrudescent parasites was higher than in 
those who later had recurrent infections at day 0 (Fig. 3). 
This suggests that sustained submicroscopic infection in 
children with recrudescences was not responsible for the 
difference in antibody levels between these two groups 
of children. One explanation for the difference is that 
the ability to recognize heterologous parasites promotes 
chronic asymptomatic infection as previously proposed 
by others [9, 23–25].
Discussion
Antibodies that bind parasite-encoded antigens on the 
surface of infected red blood cells (variant surface anti-
gens, VSA) have been implicated in alleviating specific 
pathogenic interactions between parasite ligands and 
endothelial host receptors [26], but far less is known 
about the role of anti-VSA antibodies in benefiting par-
asite survival. From an evolutionary perspective, it is 
expected that natural selection favours parasite immune 
evasion strategies, including the display of VSAs, that 
increase survival in the form of asymptomatic mainte-
nance of transmission reservoirs.
The transition from P. falciparum infections that trigger 
disease to asymptomatic infections is well documented 
in populations with high re-infection rates, but the exact 
nature of the host-parasite interactions that orchestrate 
this survival strategy of the parasite has been difficult to 
study, and recurrent P. falciparum infections in paediat-
ric patients within an age bracket that encompasses the 
switch from symptomatic to asymptomatic infections 
could provide a useful readout.
Children who received treatment for malaria were 
recruited and were then followed-up to detect recur-
rence of infections. Stratification of recurrent infections 
in recrudescent primary infections or new second-
ary infections gave us a functional in  vivo readout to 
assess the effects of anti-VSA responses determined at 
baseline.
M
FI
 
M
FI
 
119 d35 
150 d42 
171 d21 
171 d76 
178 d42 
233 d35 
245 d63 
245 d84 
Homologous  
recognition 
Heterologous 
recognition 
Control 
sera 
Time (days) 
Serum 
Isolate 
0 14 0 14 0 14 0 14 
0 0 recur recur recur 0 all 
+ _ + 
0 
0.5 
1.5 
1.0 
10 
5 
0.8 
0.6 
0.4 
0505-001- 0 
a b
Fig. 2 Recurrent infections exploit gaps in antibody repertoire against surface of infected red blood cells. a Homologous surface recognition of 
individual recurrent isolates, where the day of each recurrent parasitaemia is set at day 0. b Homologous recognition of all isolates as well as heter-
ologous recognition is shown. Homologous recognition of the isolates is shown in red, and heterologous recognition of the same isolates is shown 
in blue. For comparison, recognition of all the isolates by hyperimmune and nonimmune sera is also shown, in gray. The sera used was taken at day 
0 (at the uptake of the patient in the study), or at day 14 (convalescent sera), as indicated. The isolates were divided into baseline and recurrent iso-
lates, as indicated below the graph. Homologous sera taken before recurrence recognizes the recurrent parasites less than their overall recognition 
by heterologous sera (P = 0.063). MFI: Mean fluorescence intensity
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The pattern of antibody responses relating to malaria 
and recurrent infections were consistent with previous 
studies showing that episodes of disease are associated 
with specific gaps in the anti-VSA repertoire [14–16]. 
There was a tendency for antibodies in heterologous sera 
to recognize recurrent isolates to a higher degree than 
antibodies in day 14 sera recognized parasites from sub-
sequent homologous recurrent isolates.
Persistent primary infections were detected as mild or 
asymptomatic recrudescences in patients with higher 
than average heterologous recognition capacity meas-
ured at day 0. This is consistent with a potential role of 
anti-VSA antibodies maintaining chronic infections [9, 
23–25]. Recker et al. have proposed a model in which a 
higher (transient) cross-reactive immune response can 
potentially slow down the development of long-lived var-
iant specific responses, thereby prolonging the duration 
of infection [23–25].
A model in which anti-VSA antibodies help sustain 
chronic infections helps to explain previous observa-
tions of higher than average risk of recrudescent infec-
tions in young children [3, 27]. This phenomenon in early 
childhood may be best explained by the immaturity of 
acquired immune mechanisms that directly contribute to 
the elimination of infections, and that maturity of these 
effector mechanisms may be a prerequisite for develop-
ing tolerance to subpatient, persistent infections.
This pilot study is limited by a small sample size. Recru-
descences are rarely observed after highly efficacious 
artemisinin-combination therapy, and the definition of a 
recrudescent infection was based on a repeat polymor-
phism of a single, if highly variable, gene (MSP2). This 
method is reliable at a population level, but has limita-
tions at the individual level because there will always be 
a bias toward majority genotypes. Studies in children 
also constrain the amount of sample volume, here only 
one measurement per isolate-serum pair tested was per-
formed. Future larger studies will be required to confirm 
the hypotheses set out in this study.
It would be very interesting to make a detailed com-
parison of expressed VSA from recrudescent parasites 
in comparison with those that are isolated at day 0. It 
was not possible to do this accurately in this study 
because blood for which white blood cells had not been 
removed was used. Standard conditions for DBL-alpha 
tag amplification cannot be used in the presence of high 
levels of human RNA. A preliminary analysis using 
amplification at higher temperature was performed and 
no major changes in the profile of var genes expressed 
at different time points was observed. Specific studies 
to analyse such differences in transcriptome between 
isogenic parasites at different points during the estab-
lishment of chronic infections would be of great value 
in understanding of how these infections become 
established.
Conclusions
In short, here data is presented that support the “hole 
in the wall” model, i.e. a framework for explaining how 
the parasite exploits gaps in the anti-VSA repertoire of 
the host. It is suggested that this model may be key to 
understanding how chronic infections are established in 
humans. First data is provided to support the hypoth-
esis that a more complete anti-VSA antibody reper-
toire acquired after repeated infections could favour 
the transition from an uncomplicated malaria episode 
to an asymptomatic carrier status. These findings must 
be confirmed in larger studies, but it opens up to new 
interpretations of immunological data, and to the usage 
of recrudescence as an alternative, possibly more useful 
resource to measure immunity to malaria.
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Fig. 3 Patients harbouring primary isolates that subsequently 
recrudesced have higher background recognition than patients that 
eliminated primary infections (P = 0.059). Shown here is the mean 
fluorescence intensity (MFI) of the heterologous recognition (of 14 
isolates) by sera from 12 patients who eliminated their infections 
(and were later reinfected) (blue) compared to the 6 patients with 
recrudescences (red). The results are further divided into sera from 
day 0 (acute) and day 14 (convalescence) to show that the measured 
immune response is relatively stable, i.e. does not fluctuate from 
day to day, and is not due to submicroscopic infections still present 
in children with recrudescences in day 14 sera. Boxes show the 
interquartile range, whiskers the 5th–95th percentile and the median 
is shown as a horizontal bar. Single measurements outside the 5th–
95th percentile are shown individually
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